The European Society of Breast Cancer Specialists (EUSOMA) has awarded the Institut Normand du Sein (INS) at the Centre François Baclesse its European certification label.
Baclesse, 1st French center to obtain EUSOMA European certification
This certification is the most demanding in Europe in terms of breast cancer care. It requires not only the availability of all diagnostic and treatment techniques, but also a database for collecting and prospectively evaluating the indicators needed to monitor the quality of care.
Every year, theInstitut Normand du Sein at the Centre François Baclesse treats more than 1,000 new women with breast cancer in the region, and monitors their progress over time.
This experience and our concern to deliver high-quality care as part of a comprehensive approach (through all medical and surgical techniques, but also in terms of supportive care) has made INS the 1st French center (and currently the only one) to obtain this certification. to obtain this certification.
Institut Normand du Sein (INS)
The INS brings together and federates all the teams and services specializing in the diagnosis and treatment of breast cancer at the Centre François Baclesse :
- Medical imaging platform (mammography, ultrasound, CT, MRI, PET) providing access to all screening, diagnostic and interventional radiology procedures;
- Surgical platform for all carcinological and reconstructive surgery procedures;
- 40-bed day hospital for chemotherapy and targeted therapies;
- Radiotherapy department equipped with state-of-the-art equipment, and in particular an intraoperative radiotherapy device dedicated to breast cancer;
- Medical oncology team dedicated to breast cancer;
- Nursing team dedicated to monitoring the progress of patients undergoing treatment;
- Structuring the prescription of oral therapies within the framework of tripartite consultations (oncologist, pharmacist, nurse);
- BioPathology Department, combining the Pathology Department for diagnosis, the Oncogenetics Department and the Cancer Biology and Genetics Laboratory for follow-up of familial forms;
- Supportive care platform offering a wide range of treatments (pain, nutrition, psychological support, social services, socio-aesthetics, auriculotherapy, sophrology, relaxation, onco-sexuality, functional rehabilitation and lymphology, adapted physical activity, onco-geriatrics...);
- Clinical research service providing access to therapeutic innovation within the framework of national and international clinical trials. The onco-senology team plays an active role in the Unicancer breast group (network of cancer centers).
The EUSOMA label in the context of the COVID-19 epidemic
Obtaining such a label underlines the importance of complying with a certain number of quality criteria, in particular particularly with regard to treatment times, which can lead to loss of opportunity particularly in oncology.
The COVID-19 epidemic must not lead to :
- Delayed diagnosis for patients with symptoms that may be related to incipient cancer;
- a delay in treatment for those who have already begun their course of treatment.
All healthcare professionals (private practices, clinics, hospitals and cancer centers) have mobilized and organized to minimize the risk of COVID-19 contamination for patients, carers and staff, while ensuring continuity of care, with a gradual resumption of consultations.
